‘Therapeutic Advances in Functional Gastrointestinal Disease: Irritable Bowel Syndrome’

‘Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome’ by Alexandru Gaman, Maria Cristina Bucur and Braden Kuo Ther Adv Gastroenterol (2009) 2(3) 169-181 [DOI: 10.1177/1756283X08103656]

In this article, the authors stated that FDA approval for lubiprostone (Amitiza) was pending. This was correct at time of going to press; however, the FDA approved Amitiza for IBS-C in adult women in April 2008. We trust this clarifies the situation.